Stockholders' Equity (Deficit)

12 Months Ended

Mar. 31, 2023

Stockholders' Equity Note [Abstract]

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)

Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Company’s Board of Directors (the “Board”).

In July 2022, the Company’s quarterly dividend was raised from $0.47 to $0.54 per common share for dividends declared on or after such date by the Board. The Company declared regular cash dividends of $2.09, $1.83, and $1.67 per share for the years ended March 31, 2023, 2022, and 2021, respectively. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company’s future earnings, financial condition, capital requirements, and other factors.

Share Repurchase Plans

The Board has authorized the repurchase of McKesson’s common stock. Stock repurchases may be made from time-to-time in open market transactions, privately negotiated transactions, through accelerated share repurchase (“ASR”) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Company’s stock price, corporate and regulatory requirements, tax implications, restrictions under the Company’s debt obligations, and other market and economic conditions. During the last three fiscal years, the Company’s share repurchases were transacted through both open market transactions and ASR programs with third-party financial institutions. The ASR programs discussed below were designed to comply with Rule 10b5-1(c).

Information regarding share repurchase activity over the last three fiscal years were as follows:

	Share Repurchases (1)
(In millions, except price per share data)		Total Number of Shares Purchased (2)	Average Price Paid Per Share		Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs
Balance, March 31, 2020					$	1,535
Share repurchase authorization increase in fiscal 2021					2,000
Shares repurchased - Open market (3)		4.7	$	160.33	(750)
Balance, March 31, 2021					2,785
Shares repurchased - May 2021 ASR		5.2	$	193.22	(1,000)
Shares repurchased - Open market		4.6	$	217.73	(1,007)
Share repurchase authorization increase in fiscal 2022					4,000
Shares repurchased - February 2022 ASR (4)		4.8	$	265.56	(1,500)
Balance, March 31, 2022					3,278
Shares repurchased - February 2022 ASR (4)		0.3	$	295.16	—
Shares repurchased - May 2022 ASR		3.1	$	321.05	(1,000)
Share repurchase authorization increase in fiscal 2023					4,000
Shares repurchased - December 2022 ASR		2.6	$	369.20	(972)
Shares repurchased - Open market (5)		4.7	$	363.24	(1,693)
Balance, March 31, 2023					$	3,613

(1)This table does not include the value of equity awards surrendered to satisfy tax withholding obligations or forfeitures of equity awards.

(2)The number of shares purchased reflects rounding adjustments.

(3)Of the total dollar value, $8 million was accrued within “Other accrued liabilities” in the Company’s Consolidated Balance Sheet as of March 31, 2021, included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2022, for share repurchases that were executed in late March 2021 and settled in early April 2021.

(4)In February 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.5 billion of the Company’s common stock. The total number of shares repurchased under this ASR program was 5.1 million shares at an average price per share of $295.16. The Company received 4.8 million shares as the initial share settlement in the fourth quarter of fiscal 2022 based on an initial share purchase price, and in May 2022, it received an additional 0.3 million shares upon the completion of this ASR program.

(5)Of the total dollar value, $27 million was accrued within “Other accrued liabilities” in the Company’s Consolidated Balance Sheet as of March 31, 2023 for share repurchases that were executed in late March 2023 and settled in early April 2023.

Accumulated Other Comprehensive Loss

Information regarding changes in the Company’s accumulated other comprehensive loss by component were as follows:

	Foreign Currency Translation Adjustments
(In millions)	Foreign Currency Translation Adjustments, Net of Tax (1)		Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax (2)		Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax		Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax		Total Accumulated Other Comprehensive Loss
Balance, March 31, 2020	$	(1,780)	$	138	$	49	$	(110)	$	(1,703)
Other comprehensive income (loss) before reclassifications	312		(175)		(36)		(2)		99
Amounts reclassified to earnings and other (3)	47		—		—		24		71
Other comprehensive income (loss)	359		(175)		(36)		22		170
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests	(60)		(1)		—		8		(53)
Other comprehensive income (loss) attributable to McKesson	419		(174)		(36)		14		223
Balance, March 31, 2021	(1,361)		(36)		13		(96)		(1,480)
Other comprehensive income (loss) before reclassifications	(51)		41		18		31		39
Amounts reclassified to earnings and other (4)	71		(1)		(4)		10		76
Other comprehensive income	20		40		14		41		115
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests	5		(6)		—		—		(1)
Other comprehensive income attributable to McKesson	15		46		14		41		116
Exercise of put right by noncontrolling shareholders of McKesson Europe AG	(158)		—		—		(12)		(170)
Balance, March 31, 2022	(1,504)		10		27		(67)		(1,534)
Other comprehensive income (loss) before reclassifications	(329)		112		10		28		(179)
Amounts reclassified to earnings and other (5)	1,027		(136)		(73)		34		852
Other comprehensive income (loss)	698		(24)		(63)		62		673
Less: amounts attributable to noncontrolling interests	41		—		—		3		44
Other comprehensive income (loss) attributable to McKesson	657		(24)		(63)		59		629
Balance, March 31, 2023	$	(847)	$	(14)	$	(36)	$	(8)	$	(905)

(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Europe and Canada into the Company’s reporting currency, U.S. dollars.

(2)Amounts before reclassifications recorded in fiscal 2023, fiscal 2022, and fiscal 2021 include gains (losses) of $7 million, $73 million, and $(118) million, respectively, related to net investment hedges from Euro-denominated notes and gains (losses) of $28 million, $(4) million, and $(119) million, respectively, related to net investment hedges from cross-currency swaps. These amounts are net of income tax benefit (expense) of $(33) million, $(23) million, and $62 million in fiscal 2023, fiscal 2022, and fiscal 2021, respectively.

(3)Primarily includes adjustments for amounts related to the contribution of the Company’s German pharmaceutical wholesale business to a joint venture, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures” and Financial Note 5, “Other Income, Net.” These amounts were included in the fiscal 2021 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within “Selling, distribution, general, and administrative expenses” in the Consolidated Statement of Operations.

(4)Primarily includes adjustments for amounts related to the sale of the Company’s Austrian business, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within “Selling, distribution, general, and administrative expenses” in the Consolidated Statement of Operations.

(5)Primarily includes adjustments for amounts related to the divestitures of the E.U. disposal group in October 2022, including the impact of amounts previously attributed to the noncontrolling interest in McKesson Europe, and the U.K. disposal group in April 2022, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” These amounts were included in the fiscal 2023 and fiscal 2022 calculations of charges to remeasure the assets and liabilities of the disposal groups to fair value less costs to sell recorded within “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations. Amounts reclassified to earnings and other includes a net income tax impact of $6 million.